Associated tags: Light, Necrosis, Immunogenic cell death, Tumor microenvironment, National Cancer Institute, Pharmaceutical industry, SAN, Patient, Head, Conference, Safety, Data analysis, HNSCC, American Head
Locations: JAPAN, UNITED STATES
Safety,
Poster,
Carcinoma,
Research,
ASCO,
Thomas Jefferson University,
Society,
Physician,
Photoimmunotherapy,
Convention,
Otorhinolaryngology,
Annual general meeting,
SAN,
Pharmaceutical industry SAN DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced that it will present a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in Chicago, Illinois from May 31 through June 4, 2024.
Key Points:
- SAN DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced that it will present a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in Chicago, Illinois from May 31 through June 4, 2024.
- Rakuten Medical will also have a booth in the Exhibit Hall.
- The Company medical team will be pleased to welcome ASCO participants at booth #12118.
- First Author: Takeshi Shinozaki, Department of Head and Neck Surgery, National Cancer Center Hospital East, Japan
For more information and update, follow Rakuten Medical on LinkedIn or visit Rakuten Medical's booth at ASCO 2024.
Ephrin A2,
Mouse,
Nonsteroidal anti-inflammatory drug,
Necrosis,
Blood,
Poster,
Thromboxane A2,
Research,
Edema,
Neutrophil,
Light,
Patient,
Neoplasm,
Head,
AACR,
Meloxicam,
SAN,
Vaccine In the study presented in this poster, Rakuten Medical developed a mouse tumor model to assess edema following photoimmunotherapy and evaluated various steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) for edema reduction using the model.
Key Points:
- In the study presented in this poster, Rakuten Medical developed a mouse tumor model to assess edema following photoimmunotherapy and evaluated various steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) for edema reduction using the model.
- It was also confirmed that the reduction in edema with meloxicam was not associated with a loss of therapeutic benefit based on measurement of tumor growth.
- Control mice did not generate edema, but mice treated with conjugate plus light showed a light-dose dependent increase in edema volume which peaked at 6h post light delivery.
- The reduction in edema with meloxicam did not have negative impact on tumor growth inhibition.
I would like to thank our many investors for having valued our achievements and great potential.
Key Points:
- I would like to thank our many investors for having valued our achievements and great potential.
- Rakuten Medical also welcomed Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA region, to its Board of Directors.
- Darwazah is an experienced executive with more than 38 years of pharmaceutical industry experience gained through serving in various positions within the Hikma Group.
- In making this investment and appointment to the Board of Directors, Darwazah commented, "I am honoured to join Rakuten Medical's board.
Head,
SAN,
American Head,
Sakigake,
Neoplasm,
ASCO,
SITC,
Hope,
Rakuten,
Society,
Safety,
Biomarker,
Health,
Clinical trial,
Immunotherapy,
Abstract,
Dentistry Mickey Mikitani, Co-CEO of Rakuten Medical, said, "Witnessing the surge in findings on Alluminox treatment shared at prestigious conferences around the world fills me with immense pride.
Key Points:
- Mickey Mikitani, Co-CEO of Rakuten Medical, said, "Witnessing the surge in findings on Alluminox treatment shared at prestigious conferences around the world fills me with immense pride.
- We would like to thank all the dedicated healthcare professionals worldwide who share their excitement for this innovative technology and the potential of the Alluminox™ platform.
- Together with the medical community, we remain committed to advancing this treatment and shaping the future of patient care."
- With the increase in the number of treatment cases in the clinic, a range of findings on the Alluminox treatment have been reported, including treatment results and management of adverse events.
Retrieved on:
Thursday, December 14, 2023
SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy treatments based on its proprietary Alluminox™ platform, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024.
Key Points:
- SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy treatments based on its proprietary Alluminox™ platform, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024.
- Rakuten Medical's Co-Chief Executive Officer and President, Takashi Toraishi, and Chief Operating Officer, Abhijit Bhatia, are scheduled to present on Wednesday, January 10 at 2:30 pm PST.
- They will also participate in one-on-one investor and partnering meetings during the conference.
- Link to the webcast of Rakuten Medical's presentation at J.P. Morgan Healthcare Conference 2024
Following the completion of the presentation, a full recording and presentation slides will be available in the Events & Presentations section of the Rakuten Medical website.
Neoplasm,
Data analysis,
Biomarker,
PD-1,
Cell,
American Head,
SITC,
Immunotherapy,
Blood,
Society,
AI,
Patient,
Abstract,
Pharmaceutical industry,
Medical imaging The posters present data that may be relevant to improved clinical outcomes with treatment based on Rakuten Medical's Alluminox™ platform (photoimmunotherapy).
Key Points:
- The posters present data that may be relevant to improved clinical outcomes with treatment based on Rakuten Medical's Alluminox™ platform (photoimmunotherapy).
- Promising early evaluation data from the ASP-1929-181 study* was presented at the American Head and Neck Society (AHNS) in July 2023 (Abstract #: S252).
- Rakuten Medical and Rakuten Institute of Technology Bengaluru have collaborated on AI-based analyses of patient samples since 2020.
- The study results suggest that lower frequencies of CD8+ T cells in the blood at screening correlate with treatment response.
Retrieved on:
Thursday, November 2, 2023
SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company will present at the 14th Annual Jefferies London Healthcare Conference being held in London, UK, on November 14-16, 2023.
Key Points:
- SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company will present at the 14th Annual Jefferies London Healthcare Conference being held in London, UK, on November 14-16, 2023.
- Takashi Toraishi, Co-Chief Executive Officer and President, and Abhijit Bhatia, Chief Operating Officer are scheduled to speak at 10:30 am GMT, Tuesday, November 14.
- They will also participate in one-on-one investor and partnering meetings during the conference.
- The live webcast of the presentation can be accessed by the following link.
Retrieved on:
Thursday, August 10, 2023
SAN DIEGO, Aug. 10, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform today announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA).
Key Points:
- SAN DIEGO, Aug. 10, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform today announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA).
- Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical's pipeline using its photoimmunotherapy technology platform, Alluminox™, in all its MENA markets.
- With Hikma's strong regional footprint and medical expertise, we expect the Alluminox™ platform to make significant progress in MENA."
- * Rakuten Medical's therapies based on Alluminox™ platform are investigational outside of Japan, and not approved in MENA for investigational or commercial use.
Safety,
Head,
American Head,
MD Anderson Cancer Center,
Data analysis,
Patient,
EGFR,
SAN,
Division,
University,
HNSCC,
CR,
PD-1,
Conference,
ORR,
Pharmaceutical industry PD-1 therapy is used to treat various tumor types including head and neck cancer.
Key Points:
- PD-1 therapy is used to treat various tumor types including head and neck cancer.
- The preliminary results seen in this study warrant further study to evaluate its potential as a new innovative treatment for recurrent head and neck cancer.
- ASP-1929-181 is a Phase 1b/2, open-label study of Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy in EGFR expressing advanced solid tumors (ClinicalTrials.gov Identifier: NCT04305795 ).
- Primary endpoints of this study include safety, tolerability, and tumor response of the Alluminox treatment using ASP-1929 in combination with anti-PD1 therapy.
CT,
PIT,
Society,
PMID,
SNMMI,
Fluorescence,
Molecular imaging,
Society of Nuclear Medicine and Molecular Imaging,
Clinical trial,
Shimadzu,
Cancer,
PET,
Head,
Cell,
Cytoplasm,
Development,
National Cancer Institute,
Cooperative research and development agreement,
Metabolism,
Patient,
Data analysis,
Acquisition,
Charles François Duhoux,
SAN,
Annual general meeting,
HNSCC,
Squamous-cell carcinoma,
NCI,
EPUB,
NIH,
Neck,
Safety,
18F-FDG,
Pharmaceutical industry,
Medical imaging SAN DIEGO, June 30, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting held from June 24 to 27. ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (photoimmunotherapy: PIT) using an antibody-dye conjugate ASP-1929 with fluorescence imaging (ClinicalTrials.gov Identifier: NCT05182866) in patients with operable primary or recurrent head and neck squamous cell carcinoma (HNSCC) or cutaneous squamous cell carcinoma (cuSCC).
Key Points:
- ASP-1929-103 is the very first clinical trial of Alluminox treatment in operable cancer.
- As part of this trial, early time point (1 day) 18F-FDG PET/CT imaging was investigated as a potential response indicator of Alluminox treatment.
- The preliminary, descriptive imaging analysis based on interim evaluation of 6 patients in ASP-1929-103 study presented during the meeting showed that 18F-FDG PET/CT imaging demonstrates a therapeutic response 1 day after Alluminox treatment using ASP-1929.
- ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (PIT) using an anti-EGFR antibody-dye conjugate, ASP-1929 with fluorescence imaging in patients with operable primary or recurrent HNSCC or cuSCC.
